Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
And not many are selling either. Holders believe there is a great deal more upside than risk at this SP.
It doesn't seem like you're familiar with the background to Sprinter or the reasons for the endpoints that were set. Sadly it also doesn't look like you're genuine in your contributions to this board either.
All the best and into the green bin you go Professional. Off you pop.
"Trust us this different than last time we tried" Bingo, you've got it - it's now targeted using newly developed (Casanova Group) tests that weren't available when Sprinter was available.
It wasn't a statement at the AGM that a BP will acquire them after successful P2 results. It was that both BP and non-commercial organisations are waiting on this data before making any move. "P2 trial data required to unlock the flood gates" was the phrase used.
What that means of course is speculation - but you can narrow it down to acquisition/JV/US Platform Trial. The key of course is hitting primary endpoints in P2. My guess would be a JV - but it's a guess.
Ghia - if you want to split hairs on the start of winter, then I'll bet that SNG commence their first trial BEFORE your official Winter.
I'm not happy it's taken so long to get to this point, but I'm satisfied with the plan - it makes sense and its the least risky path forward from here.
You can interpret information that way if you like. The whole point of the targeted plan is to keep it to a small and easily manageable trial for SNG to run without the need for a partner. The P2 trials that are being run will also be run concurrently - so even if 1 trial is delayed, there will still be others that conclude within the expected time period.
BP and other organisations are waiting for this data to be provided before making a move.
You have to remember that they weren't far away from hitting their secondary endpoint WITHOUT a targeted approach. With the advances in assay test due to covid they can configure trials now that could only be dreamt of when they ran Sprinter.
Morning all. This is just a quick point to correct "Professional's" comment. The stated 18mth timeline is incorrect.
P2 trials commencing this winter would be in the region of 30 patients each and focused on patients with indicators that are likely to provide a strong signal. So valuable data (and hopefully the hitting of primary endpoints) would likely occur in much less than 12 months.
I agree Manifesto. There's a lot of conversations being had by the SNG team with authorities and potential partners - to the extent that they will retain all current headcount, who are working flat out.
There is very much a focus by the BOD on improving attractiveness to BP within the next 12 months. This will in turn be reflected in the SP.
Andy - If you had attended the AGM you would know that the trial protocol and primary endpoints focused on recovery time were demanded by the authorities. SNG had no choice but to focus the trial on what they did. "Force Majeure" was stated by Simon Shaw.
*every year during Winter
SSH responded strongly to the question of whether the product cost of SNG001 would be good value to health services.
He pointed out that every year hospitals are brought to their knees purely by respiratory viruses.
He also pointed out that the world is now due a big flu wave since the populations flu immunity has been dramatically reduced by masks and social distancing.
SSH said that covid is particularly unpredictable, unlike flu and rsv. This means that a new nasty variant could materialise at any moment from anyone infected. The medical world are still very worried about covid and omicron has given people/governments a false sense of security. SSH said vaccine evasion is a case of when not and not if. He also said we are due to a big wave of flu (potentially this winter) as our overall flu immunity has diminished after 2 years of masking and distancing. A significant proportion of covid patients that are hospitalised are also infected by other viruses due to covid impacting their immune system. SNG001 treats all respiratory viruses a patient is suffering with - unlike other covid treatments
Positive AGM overall. Full team being retained as there is so much work to be done and so many conversations being had with platform trials and potential partners. Focus is on getting onto a trial and getting more data - Simon Shaw said this will improve the attractiveness of SNG to BP.
SSH quite vocal when long covid was mentioned. Very excited about the potential for interferon. Phil Monk said long covid data wont be included in first peer reviewed paper. It will follow in due course...
Simon Shaw said their is a head of steam building with conversations 'across the pond'.
Doc83, you're right we shouldn't see them as investment gods but we do have to consider on what basis are they investing millions more in what is currently a loss making investment for them. Surely it's not the case that they're blindly bringing their average down on the hope it might recover.
One has to presume they have faith/belief/knowledge that the treatment works but the trial failed. Perhaps their investigations into the A2 US trial last year gave them confidence that SNG is worth much more than the current SP indicates?
Andy - So you've said with conviction that Polygon have loaded up more after Sprinter results to reduce their average and push aggressively for a buyout at a price higher than it is currently to minimise their losses
But in the same posts, you say its disgusting that anyone would say this share is worth investing in presently.
Surely your first claim supports a rise in the SP?
Andy - So you're saying that Polygon have loaded up more to reduce their average and push aggressively for a buyout at a price higher than it is currently to minimise their losses
But in the same post, you say its disgusting that anyone would say this share is worth investing in presently.
Surely your first claim supports a rise in the SP?
Andy - when did you sell out? I can only see you mentioning that you bought more at 24p on 28th Feb - which doesn't fit with your claim
Andy - Would you mind sharing when you sold all your shares at 33p and then bought them all back at 18p?
Andy - so sounds like you've firmed up on the SP halving in the near term from here. Why don't you sell your 45K shares?
Or do you typically hold when you expect shares to drop?
Burstead - I'm curious as to your own personal reasons for investing in SNG? You've been incredibly active on LSE but only since a week after the SPRINTER trial results were announced. What's drawn you in to spend so much time on here?
Burstead - Let's see how the ongoing discussions with the US NIH go. There are a lot of supporters there that really want this treatment to work but need to work out a way to trial it that is going to provide sufficient signal.
They still don't have a broad spectrum anti-viral they can use and Mabs are never going to be an answer when it comes to pandemic preparedness.